Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds
Rexahn Pharmaceuticals, Inc. (NYSE: RNN) today announced that the Japanese Patent Office has issued to the Company patent No. 4,934,432, entitled “Quinazoline Derivatives and Therapeutic Use Thereof.” This new patent covers Rexahn's anti-cancer candidate RX-1792 and related compounds, and a composition for treating anti-proliferative and anti-tumor activities.
Rick Soni, President of Rexahn, noted, “We are very pleased to obtain this additional patent coverage for RX-1792 in Japan, which broadens and strengthens our global intellectual property position. RX-1792 continues to demonstrate exciting anti-proliferative and anti-tumor effects in preclinical studies, and we look forward to accelerating its development.”
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.